4588 — Oncolys Biopharma Share Price
0.000.00%
Last trade - 00:00- ¥15bn
- ¥13bn
- ¥63m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.88 | ||
| Price to Tang. Book | 9.88 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 231.12 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -117.44% | ||
| Return on Equity | -106.71% | ||
| Operating Margin | -3096.36% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 1,303.84 | 314.18 | 642.49 | 976.18 | 63.04 | n/a | n/a | -17.86% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Oncolys BioPharma Inc. is a biopharmaceutical company. The Company operates in two business segments. Pharmaceutical business segment is engaged in the research, development, manufacture and marketing of pharmaceuticals. Diagnostic reagents business segment is engaged in the research, development, manufacture and marketing of diagnostic reagents and equipment, as well as the provision of inspection service. The Company's main pipeline includes OBP-301 (Telomelysin), an oncolytic virus; OBP-801, an epigenetic anticancer drug and OBP-601 for the treatment of human immunodeficiency virus (HIV) infection, among others.
Directors
- Yasuo Urata PRE (58)
- Yasushi Rokutanda MDR (50)
- Naoki Kobayashi EDR (54)
- Yasunari Kashihara OTH (48)
- Keiji Yoshimura DRC (58)
- Katsuyuki Nagai NED (58)
- Fumio Urano IND (70)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 18th, 2004
- Public Since
- December 6th, 2013
- No. of Shareholders
- 14,058
- No. of Employees
- 34
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 20,872,862
- Address
- Toranomon Towers Office, MINATO-KU, 105-0001
- Web
- https://www.oncolys.com/
- Phone
- +81 354721578
- Auditors
- Ernst & Young ShinNihon LLC
Upcoming Events for 4588
Dividend For 4588.T - 0.0000 JPY
Similar to 4588
ASKA Pharmaceutical Holdings Co
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings Co
Tokyo Stock Exchange
CanBas Co
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
What is the Oncolys Biopharma share price?
As of Today at 19:16 UTC, shares in Oncolys Biopharma are trading at ¥698. This share price information is delayed by 15 minutes.
How has the Oncolys Biopharma share price performed this year?
Shares in Oncolys Biopharma last closed at ¥698 and the price had moved by +12.4% over the past 365 days. In terms of relative price strength the Oncolys Biopharma share price has underperformed the Nikkei 225 Index by -14.99% over the past year.
What are the analyst and broker recommendations for Oncolys Biopharma?
There is no consensus recommendation for this security.
What is the Oncolys Biopharma dividend yield?
Oncolys Biopharma does not currently pay a dividend.
Does Oncolys Biopharma pay a dividend?
Oncolys Biopharma does not currently pay a dividend.
When does Oncolys Biopharma next pay dividends?
Oncolys Biopharma does not currently pay a dividend.
How do I buy Oncolys Biopharma shares?
To buy shares in Oncolys Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Oncolys Biopharma?
As of the previous close price of ¥698, shares in Oncolys Biopharma had a market capitalisation of ¥15bn.
Where are Oncolys Biopharma shares listed?
Here are the trading details for Oncolys Biopharma:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4588
What kind of share is Oncolys Biopharma?
Based on an overall assessment of its quality, value and momentum Oncolys Biopharma is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Oncolys Biopharma share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Oncolys Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oncolys Biopharma. Over the past six months, its share price has outperformed the Nikkei 225 Index by +5.64%.
As of the last closing price of ¥698, shares in Oncolys Biopharma were trading +16.93% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Oncolys Biopharma PE Ratio?
The Oncolys Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥698.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Oncolys Biopharma?
Oncolys Biopharma's management team is headed by:
- Yasuo Urata - PRE
- Yasushi Rokutanda - MDR
- Naoki Kobayashi - EDR
- Yasunari Kashihara - OTH
- Keiji Yoshimura - DRC
- Katsuyuki Nagai - NED
- Fumio Urano - IND